22nd Century Group Announces First Production of VLN® Cigarettes for Retail Sale BUFFALO, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco,...

22nd Century Group VP of Regulatory Science to Participate in FDLI Panel in Response to Recent FDA Action on Comprehensive Plan and Reduced Nicotine Mandate Company Supports This Week’s Positive FDA Action on E-Cigarettes, Demonstrating the Agency’s Commitment to Providing Adult Smokers with Alternatives to Highly Addictive CigarettesApplauds FDA’s Active...

22nd Century to Present at SNN Network Investor Conference on August 19 BUFFALO, N.Y., Aug. 17, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and...

22nd Century Group to Ring Nasdaq Closing Bell Today, August 16 BUFFALO, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (formerly NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm...